Genomics and Therapeutics of Hereditary Eye Disease
A special issue of Genes (ISSN 2073-4425). This special issue belongs to the section "Human Genomics and Genetic Diseases".
Deadline for manuscript submissions: closed (31 December 2020) | Viewed by 52141
Special Issue Editor
Interests: genomics; genetics; eye; retina; inherited retinal disease; ocular maldevelopment; transcriptomics; ophthalmology; childhood cataracts; anterior segment dysgenesis; developmental glaucoma; inherited optic neuropathy
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
We are in an era of advanced molecular diagnostics and therapeutics for patients with genetic eye diseases. Whole genome sequencing has increased the diagnostic yield and unearthed new deep intronic and non-coding regulatory variants that require further evidence of pathogenicity. Multiple phenotypes are emerging with a single gene cause, which require extensive genotype-phenotype investigations to establish correlation. To further understand hereditary eye disease, cell and animal models are used to dissect disease mechanisms, identify treatment targets, and for therapeutic pre-clinical testing. The field of therapeutics has led to the first retinal gene approval with voretigene neparovec. There are many gene therapy trials in the pipeline and novel approaches to treating these disorders including targeting common disease pathways and creating mutation-specific gene- and cell replacement strategies. In this Special Issue, we will sample the genomics, management and therapeutics that must be considered for hereditary eye diseases.
Dr. Mariya Moosajee
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Genes is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- Genetic eye disease
- Developmental eye disorders
- Inherited retinal disease
- iPSC and animal models
- Gene therapy
- Small molecule drugs
- Mutation-based therapy
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.